These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35207448)

  • 1. A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity.
    Feng Y; Xie K; Yin Y; Li B; Pi C; Xu X; Huang T; Zhang J; Wang B; Gu H; Fang J
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
    Li H; Huang C; Zhang Z; Feng Y; Wang Z; Tang X; Zhong K; Hu Y; Guo G; Zhou L; Guo W; Xu J; Yang H; Tong A
    Front Oncol; 2020; 10():1527. PubMed ID: 32984002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
    Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
    Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
    Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
    Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.
    Mews EA; Beckmann P; Patchava M; Wang Y; Largaespada DA; Wagner CR
    ACS Nano; 2022 Aug; 16(8):12185-12201. PubMed ID: 35876221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors.
    Rosenkrans ZT; Erbe AK; Clemons NB; Feils AS; Medina-Guevara Y; Jeffery JJ; Barnhart TE; Engle JW; Sondel PM; Hernandez R
    bioRxiv; 2024 May; ():. PubMed ID: 38853889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus.
    Tang J; Ma X; Chen X; Feng M; Jin X; Wang K; Wan J; Zhu X; Xie R; Dong S; Hu S; Jiang H; Xie C
    Ann Transl Med; 2022 Jul; 10(14):805. PubMed ID: 35965796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors.
    Shin SH; Ju EJ; Park J; Ko EJ; Kwon MR; Lee HW; Son GW; Park YY; Kim YJ; Song SY; Lee S; Seo BS; Song JA; Lim S; Jung D; Kim S; Lee H; Park SS; Jeong SY; Choi EK
    Cancer Cell Int; 2023 Aug; 23(1):172. PubMed ID: 37596639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
    Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
    Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
    Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
    Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
    Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.
    Sun X; Yu Y; Ma L; Xue X; Gao Z; Ma J; Zhang M
    Invest New Drugs; 2020 Jun; 38(3):722-732. PubMed ID: 31267380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers.
    Hu J; Jiang C; Zheng M; Guo Y; Tang X; Ren J; Lu D; Yu L; Gan W; Liu S; Tong A; Yang H
    Am J Transl Res; 2019; 11(8):5183-5196. PubMed ID: 31497233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
    Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
    Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody.
    Liu X; Zhelev D; Adams C; Chen C; Mellors JW; Dimitrov DS
    Transl Oncol; 2021 Dec; 14(12):101232. PubMed ID: 34601396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.